Camlin Fine Sciences Limited has approved the appointment of Thomas Videbaek as an Additional Director (Non‐Executive Independent Director) on the Board of Directors of the Company for a term of 5 years with effect from 31st March, 2021.
Thomas Videbaek, born 1960, is currently the Executive Vice President of Business Development for Novozymes, where he is responsible for nurturing and realizing the potential of the company’s new platforms.
Thomas comes to role from the company’s former BioBusiness, which he headed from 2007‐ 2013 and which encompassed business ventures outside of Novozymes’ established areas. Previously, he developed diverse key functions within the organization, spanning both the commercial and operational side of the business. He was Vice President of Sales & Customer Solutions from 2005‐2007 and served as Vice President for Supply Chain Operations from 2003‐2005.
From 1998‐2003, during the demerger, Thomas served as both Vice President for Cereal Food and Beverage Marketing and General Manager for Novozymes Switzerland. In Novo Nordisk A/S, Thomas’ roles included Director for Strategic Marketing, Food and Feed enzymes, where he set strategy for the food and feed industries. He also worked in a leadership position within the starch and textile businesses, the latter in the company’s U.S. operations.
Thomas holds a Ph.D. and a M.Sc. in Chemical Engineering from the Technical University of Denmark, as well as a B.Com. in International Business from Copenhagen Business School. He currently serves as member of the board of Evolva AG.
At around 12:48 PM, Camlin Fine Sciences was trading at Rs142.30 per piece up by Rs2.5 or 1.79% on Sensex.
Related Tags: